An Absolute Bioavailability Study of LY2835219 in Healthy Subjects Using the Intravenous Tracer Method

Trial Profile

An Absolute Bioavailability Study of LY2835219 in Healthy Subjects Using the Intravenous Tracer Method

Completed
Phase of Trial: Phase I

Latest Information Update: 03 Mar 2015

At a glance

  • Drugs Abemaciclib (Primary) ; Abemaciclib (Primary)
  • Indications Breast cancer; Cancer; Mantle-cell lymphoma; Non-small cell lung cancer
  • Focus Pharmacokinetics
  • Sponsors Eli Lilly
  • Most Recent Events

    • 25 Feb 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 09 Feb 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
    • 13 Jan 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top